{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:47Z","timestamp":1793459687837,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021564","name":"Unicancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007877","name":"Fujita Hoken Eisei Daigaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013944","name":"Institut de Canc\u00e9rologie de Lorraine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.esmoop.2021.100114","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:01:03Z","timestamp":1619136063000},"page":"100114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["Evolution of overall survival and receipt of new therapies by subtype among 20\u2009446 metastatic breast cancer patients in the 2008-2017 ESME cohort"],"prefix":"10.1016","volume":"6","author":[{"given":"T.","family":"Grinda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Antoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Blaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-H.","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Debled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patsouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Uwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jouannaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lacroix-Triki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Deluche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Robain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Courtinard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100114_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.esmoop.2021.100114_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005-2015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast."},{"issue":"6797","key":"10.1016\/j.esmoop.2021.100114_bib3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.esmoop.2021.100114_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.esmoop.2021.100114_bib5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.esmoop.2021.100114_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.esmoop.2021.100114_bib7","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol."},{"issue":"20","key":"10.1016\/j.esmoop.2021.100114_bib8","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N\u00a0Engl J Med."},{"issue":"20","key":"10.1016\/j.esmoop.2021.100114_bib9","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N\u00a0Engl J Med."},{"issue":"4","key":"10.1016\/j.esmoop.2021.100114_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N\u00a0Engl J Med."},{"issue":"6","key":"10.1016\/j.esmoop.2021.100114_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N\u00a0Engl J Med."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100114_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100114_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2019","journal-title":"JAMA Oncol."},{"issue":"9769","key":"10.1016\/j.esmoop.2021.100114_bib14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet."},{"issue":"23","key":"10.1016\/j.esmoop.2021.100114_bib15","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med."},{"issue":"11","key":"10.1016\/j.esmoop.2021.100114_bib16","doi-asserted-by":"crossref","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"JNCI J Natl Cancer Inst."},{"issue":"2","key":"10.1016\/j.esmoop.2021.100114_bib17","doi-asserted-by":"crossref","first-page":"e023568","DOI":"10.1136\/bmjopen-2018-023568","article-title":"The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)","volume":"9","author":"P\u00e9rol","year":"2019","journal-title":"BMJ Open."},{"key":"10.1016\/j.esmoop.2021.100114_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.esmoop.2021.100114_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22 000 women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer."},{"issue":"5","key":"10.1016\/j.esmoop.2021.100114_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMp1504547","article-title":"Universalism, responsiveness, sustainability\u2014regulating the French Health Care System","volume":"374","author":"Steffen","year":"2016","journal-title":"N\u00a0Engl J Med."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100114_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdv506","article-title":"Early market access of cancer drugs in the EU","volume":"27","author":"Martinalbo","year":"2016","journal-title":"Ann Oncol."},{"issue":"5","key":"10.1016\/j.esmoop.2021.100114_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.annpat.2014.08.017","article-title":"Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France","volume":"34","author":"MacGrogan","year":"2014","journal-title":"Ann Pathol."},{"issue":"6","key":"10.1016\/j.esmoop.2021.100114_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annpat.2019.04.004","article-title":"GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting","volume":"39","author":"Maran-Gonzalez","year":"2019","journal-title":"Ann Pathol."},{"issue":"11","key":"10.1016\/j.esmoop.2021.100114_bib25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med."},{"issue":"6","key":"10.1016\/j.esmoop.2021.100114_bib26","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"issue":"8","key":"10.1016\/j.esmoop.2021.100114_bib27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A\u00a0standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100114_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers11010010","article-title":"Therapy landscape in patients with metastatic HER2-positive breast cancer: data from the PRAEGNANT real-world breast cancer registry","volume":"11","author":"Lux","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"16","key":"10.1016\/j.esmoop.2021.100114_bib29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med."},{"issue":"34","key":"10.1016\/j.esmoop.2021.100114_bib30","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J\u00a0Clin Oncol."},{"issue":"10179","key":"10.1016\/j.esmoop.2021.100114_bib31","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","volume":"393","author":"Gray","year":"2019","journal-title":"Lancet."},{"issue":"15","key":"10.1016\/j.esmoop.2021.100114_bib32","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2001.19.15.3516","article-title":"18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer","volume":"19","author":"Eubank","year":"2001","journal-title":"J\u00a0Clin Oncol."},{"issue":"25","key":"10.1016\/j.esmoop.2021.100114_bib33","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","article-title":"The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer","volume":"312","author":"Feinstein","year":"1985","journal-title":"N\u00a0Engl J Med."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100114_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1634\/theoncologist.2014-0273","article-title":"Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon","volume":"20","author":"Fink","year":"2015","journal-title":"Oncologist."},{"issue":"8","key":"10.1016\/j.esmoop.2021.100114_bib35","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/annonc\/mdz159","article-title":"Does adjuvant therapy reduce postmetastatic survival?","volume":"30","author":"Fink","year":"2019","journal-title":"Ann Oncol."},{"issue":"11","key":"10.1016\/j.esmoop.2021.100114_bib36","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/bjc.2011.144","article-title":"Explaining the difference in prognosis between screen-detected and symptomatic breast cancers","volume":"104","author":"Allgood","year":"2011","journal-title":"Br J Cancer."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100114_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/aje\/kwn120","article-title":"Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival","volume":"168","author":"Duffy","year":"2008","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.esmoop.2021.100114_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2020.10.012","article-title":"Evolution in the real-world therapeutic strategies in more than 20 000 women with breast cancer having received human epidermal growth factor receptor 2\u2013targeted treatments: results from the French personalized reimbursement model database (2011-2018)","volume":"141","author":"Cottu","year":"2020","journal-title":"Eur J Cancer."},{"issue":"7-8","key":"10.1016\/j.esmoop.2021.100114_bib39","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1684\/bdc.2014.1940","article-title":"Autorisation de mise sur le march\u00e9 du pertuzumab (Perjeta\u00ae) dans les cancers du sein m\u00e9tastatiques HER2 positifs","volume":"101","author":"Sabatier","year":"2014","journal-title":"Bull Cancer (Paris)."},{"key":"10.1016\/j.esmoop.2021.100114_bib40","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.7","article-title":"Final overall survival (OS) analysis from the Cleopatra study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (Pts) with Her2-positive metastatic breast cancer (Mbc)","volume":"25","author":"Swain","year":"2014","journal-title":"Ann Oncol."},{"issue":"12","key":"10.1016\/j.esmoop.2021.100114_bib41","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1002\/ijc.32402","article-title":"Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program","volume":"145","author":"Jacot","year":"2019","journal-title":"Int J Cancer."},{"key":"10.1016\/j.esmoop.2021.100114_bib42","unstructured":"Defossez G, Le Guyader-Peyrou S, Uhry Z, et\u00a0al. Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. Etude \u00c0 Partir Regist. Cancers R\u00e9seau Francim R\u00e9sultats Pr\u00e9liminaires Synth\u00e8se St.-Maurice Fra Sant\u00e9 Publique Fr. 2019:19. Available at: https:\/\/import\/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-metropolitaine-entre-1990-et-2018-tumeurs-solides-etude-a-partirlast. Accessed April 15, 2021."}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:40Z","timestamp":1761855940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2059702921000727"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100114","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of overall survival and receipt of new therapies by subtype among 20\u2009446 metastatic breast cancer patients in the 2008-2017 ESME cohort","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100114"}}